Presidio Pharmaceuticals, Inc. to Present at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL)

SAN FRANCISCO--(BUSINESS WIRE)--Presidio Pharmaceuticals, Inc. announced today that Richard Colonno, PhD, Chief Scientific Officer, will present a summary of the profile of PPI-461, a potent and selective HCV NS5A inhibitor, recently designated as a clinical candidate by Presidio.